Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium

We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-12-05
DOI
https://doi.org/10.1182/blood.2025030149
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium

Mark N Sorial, Carlos Chiattone, Mubarak M. Al-Mansour, Govind Bhagat et al.
1 citations
Blood
Lymphoma Diagnosis and Treatment
1.47
article

Early time to relapse as a survival prognosticator in nodal mature T-cell lymphomas: results from the PETAL consortium

Mark N Sorial, Carlos Chiattone, Mubarak M. Al-Mansour, Govind Bhagat, Hasmukh Jain, Stefan Klaus Barta, Henry Miles Prince, Edith Julia, Emmanuel Bachy, Estelle Verburgh, Changyu Shen, Luis Malpica, Takeshi Okatani, W. Kim, María Elena Cabrera, Salvia Jain, Robert N. Stuver, Francine M. Foss, Pier Luigi Zinzani, Massimo Federico, Eric Jacobsen
article en
1 citations

Abstract

We assessed the overall survival (OS) impact of time to relapse (TTR) in multinational cohorts with independent observational and randomized validation. Patients with nMTCL with frontline complete response were assigned to TTR12 (≤12 months) or without TTR12 based on time to progression or next therapy. OS analyses included modified landmark (m-LM), standard landmark (s-LM), and time-dependent Cox (td-Cox), adjusting for age, histology, and prognostic index for T-cell lymphoma (PIT) score. Across 452 patients, 165 (36.5%) had TTR12, 181 (40%) relapsed at ≥12 months, and 106 (23.5%) remained relapse-free. TTR12 conferred worse OS using m-LM (hazard ratio [HR], 2.14; 95% confidence interval [CI], 1.58-2.90; P< .001), s-LM (HR, 1.92; 95% CI, 1.39-2.66; P< .001); and td-Cox (HR, 5.81; 95% CI, 2.94-11.46; P< .001). Results were consistent in the independent validation cohorts. TTR12 consistently conferred worse OS irrespective of frontline stem cell transplantation or PIT score, in peripheral T-cell lymphoma, not otherwise specified (m-LM: HR, 2.32; 95% CI, 1.51-3.55; P< .001; s-LM: HR, 2.10; 95% CI, 1.33-3.31; P = .001), anaplastic large cell lymphoma (m-LM: HR, 3.34; 95% CI, 1.18-9.50; P = .023; s-LM: HR, 2.96; 95% CI, 1.02-8.81; P = .046), and angioimmunoblastic T-cell/T follicular helper cell lymphoma (m-LM only: HR, 1.92; 95% CI, 1.15-3.21; P = .013). Second-line novel therapies improved OS (second-line start to death) vs chemotherapy in TTR12 only (HR, 0.60; 95% CI, 0.37-0.97; P = .038; without TTR12: HR, 0.82; 95% CI, 0.51-1.32; P = .407). TTR12 serves as a prognostic and potential OS surrogate marker, supporting stratification of new risk groups and need for their differential treatment.

BloodVol. 147(7)
Université Claude Bernard Lyon 1 (FR), Broad Institute (US), University of Modena and Reggio Emilia (IT), Biogen (United States) (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), University of Cape Town (ZA), Lyon College (US), Homi Bhabha National Institute (IN), Columbia University Irving Medical Center (US), Japanese Red Cross Hiroshima College of Nursing (JP), Hospital of the University of Pennsylvania (US), Tata Memorial Hospital (IN), Santa Casa Hospital (BR), Peter MacCallum Cancer Centre (AU), Samsung Medical Center (KR), Groote Schuur Hospital (ZA), King Abdulaziz Medical City (SA), Yale Cancer Center (US), Hospital del Salvador (CL), Hospices Civils de Lyon (FR), Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP), Faculdade de Ciências Médicas da Santa Casa de São Paulo (BR), Dana-Farber Cancer Institute (US), Istituto di Ematologia di Bologna (IT), Azienda USL di Bologna (IT), Center for Cancer Research (US), Massachusetts Institute of Technology (US), University of Chile (CL), Columbia University (US), University of Pennsylvania (US), University of Bologna (IT)
Eli Lilly and Company, AstraZeneca, Sanofi, Gilead Sciences, Biogen, Celgene, Astex Pharmaceuticals, Mersana Therapeutics, BeiGene, Incyte, Celltrion, Seagen, Kyowa Hakko Kirin, Servier, Intas Pharmaceuticals, Irving Medical Center, Columbia University, Pharmacyclics, Daiichi Sankyo Europe, Cilag
Openalex Percentile: Top 13%
Lymphoma Diagnosis and Treatment
1.47
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.